SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London Consortium.

SARS-CoV-2 抗体免疫力跨越三大洲:西非、西印度群岛、西伦敦联盟

阅读:7
作者:Greenwood David, Hague Oliver, Kwesi-Maliepaard Eliza Mari, Redman Shanice A, Scott Flora, Anzinger Joshua J, Awandare Gordon, Bauer David Lv, Bediako Yaw, Carr Edward J, Carrington Christine Vf, Kucharski Adam, Quashie Peter, Wall Emma C, Wu Mary Y
BACKGROUND: The experience of the COVID-19 pandemic has differed across continents. We hypothesized that regional differences in SARS-CoV-2 immunity might explain this observation. We therefore established the WWW Consortium in Ghana, W Africa; Jamaica, W Indies; and W London. Here, we describe the extent to which antibody immunity differs between these geographic locations. METHODS: The WWW Consortium harmonises across the HERITAGE (Accra, Ghana), WINDFall (Kingston, Jamaica) and Legacy (London, UK) studies, establishing sharing frameworks for samples, metadata, and data; related permissions and oversight; and associated physical and cloud infrastructure. With centralised testing, we performed serological assessments across all three locations at two snapshots in 2024 (April 1(st) - August 18(th); August 19(th) - December 31(st)) using high-throughput live virus neutralization and anti-nucleocapsid IgG, including n=763 individuals. FINDINGS: We found that across all sites most participants had detectable neutralising antibody titres against JN.1 and XEC - the predominant variants in 2024. There were site-related differences in immunity: vaccine-included SARS-CoV-2 strains were better neutralised by participants from the Legacy study - Ancestral, BA.5, XBB.1.5 initially, and JN.1 after a homologous booster in autumn 2024. For HERITAGE, neutralisation of both alpha- (HCoV-229E) and beta-coronaviruses (HCoV-OC43) was higher than WINDFall suggesting a cross-coronavirus serological response in West Africa. Finally, antigenic cartography identified two distinct antibody landscapes, with JN.1 and XEC antigenically distant in Legacy, but not in HERITAGE and WINDFall. INTERPRETATION: There is international heterogeneity in SARS-CoV-2 antibody immunity. Global recommendations for vaccine strain selection should incorporate data from diverse populations to ensure accurate, equitable recommendations. FUNDING: The Wellcome Trust.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。